Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NAD refers eFoodSafety to FTC

This article was originally published in The Tan Sheet

Executive Summary

The National Advertising Division refers to the Federal Trade Commission for possible law enforcement action for Internet advertising claims the firm made about its Cinnergen dietary supplement. As part of its routine monitoring program, NAD targeted Cinnergen for health-related establishment and performance claims including: "clinically proven to control blood sugar" and "over half the patients in our clinical study were able to stop taking prescribed medication!" according to a Feb. 7 decision. The Council of Better Business Bureaus group's numerous attempts to contact eFoodSafety were unsuccessful, NAD says...

You may also be interested in...

Claims Implying Supplement Could Replace Insulin Must Go, NAD Says

Implying that's glucose-metabolism supplement Cinnergen is a replacement for normal insulin regimens is misleading, the National Advertising Division says

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts